revenue distribution by industry:

• pharmaceuticals: approx. 45%
• consumer health: approx. 20%
• crop science: approx. 35%

top 3 markets and their percentage shares:

• usa: approx. 30%
• germany: approx. 15%
• china: approx. 10%

bayer aktiengesellschaft generates the majority of its revenue from the pharmaceuticals sector, followed by crop science and consumer health. the u.s. market is the most significant individual market for bayer, attributed to its strong presence and demand in the pharmaceutical and crop science sectors.

germany and china are also important markets, with germany playing a central role as the home market and china gaining importance due to its growing demand for health products and agricultural chemicals.

production sites of bayer ag:

bayer ag operates production facilities in over 30 countries worldwide. the most important sites include:

• germany: leverkusen (headquarters), wuppertal, dormagen, and berlin.
• usa: berkeley, california and whippany, new jersey.
• china: beijing and shanghai.
• brazil: são paulo.

bayer produces a variety of products in the areas of pharmaceuticals, crop science, and consumer health. the production sites are strategically distributed across the globe to efficiently serve both local and international markets. this enables bayer to flexibly respond to regional market requirements and optimize supply chains.

focus on pharmaceuticals and biotechnology: increasing investments in research and development

agricultural sciences: expansion of digital agricultural solutions

sustainability: implementation of climate neutrality goals by 2030

bayer aktiengesellschaft pursues a strategy that is strongly focused on innovation and sustainability. in the pharmaceutical sector, the company is concentrating on the development of new drugs and therapies, particularly in the areas of oncology, cardiovascular diseases, and rare diseases.

in the agricultural sector, bayer is investing in the digitization of agriculture to increase efficiency and sustainability. this includes investments in digital platforms and technologies that help farmers optimize their yields while reducing their ecological footprint.

furthermore, bayer has set ambitious climate goals and plans to become climate neutral by 2030. this includes initiatives to reduce co2 emissions and promote sustainable practices in all business areas.

main raw materials: chemicals, seeds, pharmaceutical active ingredients

countries of origin:

• chemicals: usa, china, india
• seeds: usa, brazil
• pharmaceutical active ingredients: india, switzerland, germany

bayer aktiengesellschaft is a globally active company operating in the health and agriculture sectors. for the production of its products, bayer imports a variety of raw materials and materials.

chemicals needed for the production of plant protection products and other chemical products often come from the usa, china, and india. these countries are leading producers of basic chemicals and specialty chemicals.

seeds are mainly imported from the usa and brazil, as these countries are significant producers of agricultural seeds, especially for use in the agribusiness industry.

bayer sources pharmaceutical active ingredients from india, switzerland, and germany. india is known for its cost-effective production of generic active ingredients, while switzerland and germany are known for their high-quality pharmaceutical products.

this diversification of sources enables bayer to optimize its supply chain and minimize risks.

market share in the agricultural sector: 20% (2024, estimate)
r&d expenses: 5.3 billion euros (2023)
patent portfolio: over 7,500 active patents (2023)

bayer aktiengesellschaft possesses a significant competitive advantage, especially in the agricultural sector, where the company holds an estimated market share of 20%. this is mainly due to the acquisition of monsanto and the associated expansion of the product portfolio.

the company continuously invests in research and development, with expenses of 5.3 billion euros in 2023, strengthening its innovation capabilities and ability to introduce new products to the market. bayer also has an extensive patent portfolio with over 7,500 active patents, serving as a protective barrier against competitors and further solidifying its market position.

additionally, bayer benefits from its global presence and diversification in the pharmaceutical and consumer health sectors, making the company more resilient to market fluctuations.

institutional investor share: approx. 70% (estimated for 2025)
insider purchases/sales: no significant transactions in the last year (2024)

the institutional investor share in bayer aktiengesellschaft remains stable at around 70%. this demonstrates the continued trust of large investors in the company.

in 2024, there were no significant insider transactions, indicating a stable internal assessment of the company's development. such information is important for investors to evaluate management's confidence in the company's future performance.

market share bayer ag: estimated around 5% in the global pharmaceutical market (2025)

main competitors and their market shares:

1. pfizer inc.: approx. 8%
2. roche holding ag: approx. 7%
3. novartis ag: approx. 7%
4. johnson & johnson: approx. 6%
5. merck & co., inc.: approx. 6%
6. sanofi s.a.: approx. 5%
7. glaxosmithkline plc: approx. 5%
8. astrazeneca plc: approx. 4%
9. abbvie inc.: approx. 4%
10. bristol-myers squibb company: approx. 3%

bayer ag has a significant moat, especially due to its strong position in agrochemistry and the pharmaceutical industry. the moat is supported by a broad product range, strong brands, and continuous investments in research and development. bayer also benefits from a global presence and a diversified business model that includes both pharmaceuticals and agricultural products.

however, compared to its competitors, bayer faces challenges, especially in the pharmaceutical sector, where companies like pfizer and roche have a stronger moat due to their innovation capabilities and extensive pipelines. these companies often have specialized products and leading positions in specific therapeutic areas, giving them a competitive advantage.

overall, bayer has a solid moat, but the competition is intense, and the ability to invest in research and development and successfully bring new products to market will be crucial for its future market position.

revenue growth: 3.5% (2024) r&d expenses: 5.3 billion euros (2024) debt level: 36 billion euros (2024)

bayer aktiengesellschaft recorded a revenue growth of 3.5% in 2024. this indicates a moderate growth rate, attributed to stable demand in the core areas of pharmaceuticals and agriculture. the continuous investment in research and development, amounting to 5.3 billion euros in 2024, suggests that bayer is striving to expand its product pipeline and drive innovation.

the debt level of 36 billion euros in 2024 is an important factor for investors to consider. while this represents a significant amount, bayer has demonstrated in the past its ability to effectively manage its debts, particularly through strategic divestments and cost-cutting measures.

overall, bayer's stock could be attractive to investors interested in long-term growth opportunities, especially in the pharmaceutical and agricultural sectors. however, potential investors should carefully weigh the debt burden and associated risks.

dividend yield: 3.5% (estimated for 2025)
dividend history: continuous distribution in recent years

bayer aktiengesellschaft has regularly distributed dividends to its shareholders in recent years. the dividend yield for 2025 is estimated to be around 3.5%, based on the latest available data and the company's dividend policy.

bayer has a long tradition of dividend payments, indicating a certain reliability in distribution. the company's dividend policy aims to provide shareholders with an attractive return while also investing in future growth.

however, it is important to monitor the company's financial situation and strategic decisions, as these could influence future dividend policies.